UK-based biotech ReNeuron has announced encouraging results from an early stage trial of its cell therapy for the rare blindness-causing disease, retinitis pigmentosa (RP).
US ophthalmology technology firm EyeQue has launched VisionCheck, which it says is the world’s first automated optical device allowing consumers to measure and track their refractive error
Spark Therapeutics’ gene therapy for a rare inherited sight disorder, Luxturna has been approved in Europe, but there was still no word on price from marketing partner Novartis.
Novartis’ ophthalmology division Alcon has announced plans to build a digital platform to streamline, simplify and improve cataract surgery for surgeons and patients.
Novartis is appealing against a High Court ruling that it is lawful for the NHS to prescribe Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD)
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.